Leveraging the baculovirus-insect cell expression system for optimal AAV scale-up

David McCall, Senior Editor, BioInsights, speaks to VectorY Therapeutics’ Barbara Sanders, Co-founder and CTO, and Femke Hoeksema, Director of Process Development, about their innovative work on gene therapies for neurodegenerative diseases, including vectorized antibody treatments for amyotrophic lateral sclerosis. They also discuss the considerations and advantages in utilizing a baculovirus-based AAV production system versus other upstream viral vector production platforms.

Please enter your email to access content Read now